809MO Efficacy and safety results from the phase II study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphomaYufang Song, Jiahui Zhu, Songlin Hou et al.|Annals of Oncology|2024Cited by 1